Legarda MA, Cejalvo MJ, de la Rubia J (2020) Recent advances in the treatment of patients with multiple myeloma. Cancers 12:3576

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mohan M, Matin A, Davies FE (2017) Update on the optimal use of bortezomib in the treatment of multiple myeloma. Cancer Manag Res 9:51–63

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF (2010) Bortezomib plus Melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28:2259–2266

Article  CAS  PubMed  Google Scholar 

Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 370:1209–1218

Article  CAS  PubMed  Google Scholar 

Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395:132–141

Article  CAS  PubMed  Google Scholar 

Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J (2018) Daratumumab plus Bortezomib, Melphalan, and Prednisone for untreated myeloma. N Engl J Med 378:518–528

Article  CAS  PubMed  Google Scholar 

Maruyama D, Iida S, Machida R, Kusumoto S, Fukuhara N, Yamauchi N, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Usuki K, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Ota S, Ohtsuka E, Hanamura I, Suzuki Y, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Fukuhara S, Tsukasaki K, Nagai H (2022) Final analysis of randomized phase II study optimizing melphalan, prednisolone, bortezomib in multiple myeloma (JCOG1105). Cancer Sci 113:3267–3270

Article  CAS  PubMed  PubMed Central  Google Scholar 

Maruyama D, Iida S, Ogawa G, Fukuhara N, Seo S, Miyazaki K, Yoshimitsu M, Kuroda J, Tsukamoto N, Tsujimura H, Hangaishi A, Yamauchi T, Utsumi T, Mizuno I, Takamatsu Y, Nagata Y, Minauchi K, Ohtsuka E, Hanamura I, Yoshida S, Yamasaki S, Suehiro Y, Kamiyama Y, Tsukasaki K, Nagai H (2021) Randomised phase II study to optimise melphalan, prednisolone, and bortezomib in untreated multiple myeloma (JCOG1105). Br J Haematol 192:531–541

Article  CAS  PubMed  Google Scholar 

Maekawa K, Hirayama A, Iwata Y, Tajima Y, Nishimaki-Mogami T, Sugawara S, Ueno N, Abe H, Ishikawa M, Murayama M, Matsuzawa Y, Nakanishi H, Ikeda K, Arita M, Taguchi R, Minamino N, Wakabayashi S, Soga T, Saito Y (2013) Global metabolomic analysis of heart tissue in a hamster model for dilated cardiomyopathy. J Mol Cell Cardiol 59:76–85

Article  CAS  PubMed  Google Scholar 

Maekawa K, Ri M, Nakajima M, Sekine A, Ueda R, Tohkin M, Miyata N, Saito Y, Iida S (2019) Serum lipidomics for exploring biomarkers of bortezomib therapy in patients with multiple myeloma. Cancer Sci 110:3267–3274

Article  CAS  PubMed  PubMed Central  Google Scholar 

Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467–1473

Article  CAS  PubMed  Google Scholar 

Saito K, Ikeda M, Kojima Y, Hosoi H, Saito Y, Kondo S (2018) Lipid profiling of pre-treatment plasma reveals biomarker candidates associated with response rates and hand-foot skin reactions in sorafenib-treated patients. Cancer Chemother Pharmacol 82:677–684

Article  CAS  PubMed  Google Scholar 

Saito K, Ohno Y, Saito Y (2017) Enrichment of resolving power improves ion-peak quantification on a lipidomics platform. J Chromatogr B Analyt Technol Biomed Life Sci 1055–1056:20–28

Article  PubMed  Google Scholar 

Meregalli C (2015) An overview of Bortezomib-Induced neurotoxicity. Toxics 3:294–303

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yang Y, Zhao B, Lan H, Sun J, Wei G (2024) Bortezomib-induced peripheral neuropathy: clinical features, molecular basis, and therapeutic approach. Crit Rev Oncol/Hematol 197:104353

Article  PubMed  Google Scholar 

Dimopoulos MA, Mateos M-V, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kropff M, Spicka I, Palumbo A, Wu KL, Esseltine D-L, Liu K, Deraedt W, Cakana A, Van De Velde H, San Miguel JF (2011) Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib–melphalan–prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 86:23–31

Article  CAS  PubMed  Google Scholar 

Arnulf B, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, van de Velde H, Feng H, Cakana A, Deraedt W, Moreau P (2012) Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma. Haematologica 97:1925–1928

Article  PubMed  PubMed Central  Google Scholar 

Zhao R, Xie Y, Yang B, Wang C, Huang Q, Han Y, Yang L, Yan S, Wang X, Fu C, Wu D, Wu X (2020) Identification of metabolic biomarkers to predict treatment outcome and disease progression in multiple myeloma. Am J Cancer Res 10:3935–3946

CAS  PubMed  PubMed Central  Google Scholar 

Nagata Y, Ishizaki I, Waki M, Ide Y, Hossen MA, Ohnishi K, Miyayama T, Setou M (2015) Palmitic acid, verified by lipid profiling using secondary ion mass spectrometry, demonstrates anti-multiple myeloma activity. Leuk Res 39:638–645

Article  CAS  PubMed  Google Scholar 

Puchades-Carrasco L, Lecumberri R, Martínez-López J, Lahuerta JJ, Mateos MV, Prósper F, San-Miguel JF, Pineda-Lucena A (2013) Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission. Clin Cancer Res 19:4770–4779

Article  CAS  PubMed  Google Scholar 

Zittema D, Casteleijn NF, Bakker SJ, Boesten LS, Duit AA, Franssen CF, Gaillard CA, Gansevoort RT (2017) Urine concentrating capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy patients with renal impairment. PLoS ONE 12:e0169263

Article  PubMed  PubMed Central  Google Scholar 

Al-Ani A, Al-Jalham K, Ibrahim T, Majzoub A, Al-Rayashi M, Hayati A, Mubarak W, Al-Rayahi J, Khairy AT (2015) Factors determining renal impairment in unilateral ureteral colic secondary to calcular disease: a prospective study. Int Urol Nephrol 47:1085–1090

Article  CAS  PubMed  Google Scholar 

Ogawa T, Ishida-Kitagawa N, Tanaka A, Matsumoto T, Hirouchi T, Akimaru M, Tanihara M, Yogo K, Takeya T (2006) A novel role of L-serine (L-Ser) for the expression of nuclear factor of activated T cells (NFAT)2 in receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclastogenesis in vitro. J Bone Min Metab 24:373–379

Article  CAS  Google Scholar 

Shao Q, Deng L, Liu H, Liu Z, Chen J, Jiang F, Yan S, Fu R (2020) Involvement of MM cell-derived exosomes in T lymphocytes immune responses. Oncol Lett 20:31

CAS  PubMed  PubMed Central  Google Scholar 

Khan SA, Ilies MA (2023) The phospholipase A2 superfamily: structure, isozymes, catalysis, physiologic and pathologic roles. Int J Mol Sci 24

Glaser KB (1995) Regulation of Phospholipase A2 Enzymes: Selective Inhibitors and their Pharmacological Potential. In: August JT, Anders MW, Murad F, Coyle J (eds) Advances in Pharmacology Academic Press, pp 31–66

Sun GY, Shelat PB, Jensen MB, He Y, Sun AY, Simonyi A (2010) Phospholipases A2 and inflammatory responses in the central nervous system. Neuromolecular Med 12:133–148

Article  CAS  PubMed  Google Scholar 

Huang YH, Schäfer-Elinder L, Wu R, Claesson HE, Frostegård J (1999) Lysophosphatidylcholine (LPC) induces proinflammatory cytokines by a platelet-activating factor (PAF) receptor-dependent mechanism. Clin Exp Immunol 116:326–331

Article  CAS  PubMed  PubMed Central